stars 1 stars 2 stars 3

Onteis is developing a platform to produce non-cytotoxic treatments aimed at cancer normalization. Cancer normalization leads to the anatomical and functional reconstruction of cancerous tissues and their reintegration into the organism. This approach represents a new class of therapies designed to improve the therapeutic index (efficacy/toxicity) compared to conventional cytotoxic treatments. By avoiding cell destruction, Onteis' future treatments aim to enhance tolerance while restoring the normal function of affected tissues. Onteis develops mathematical models that take into account several levels of the organism, and precisely the level of the tissue. They are based on the work of the interdisciplinary programme “Theoretical Foundations of Biology”, hosted at the École Normale Supérieure in Paris.

Onteis Questions

Nicolas Andre is the CEO of Onteis.

1 people are employed at Onteis.

Top Onteis Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users